Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4692009

Cc1ccccc1-c1cc2nc(N)nc(N)c2c2ccn(C)c12.O=C(O)C(F)(F)F

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
DHFR P00374 7/20 0.46
ADORA2A P29274 1/20 0.38
PIK3CD O00329 2/20 0.37
SLC2A1 P11166 3/20 0.37
C1S P09871 1/20 0.36
PAX8 Q06710 1/20 0.34
F2R P25116 1/20 0.33
HSP90AA1 P07900 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL4691901 0.92 DHFR (0.40) DHFRPIK3CDSLC2A1C1SPAX8
Trifluoroacetic Acid SCHEMBL4694171 0.90 DHFR (0.41) DHFRADORA2ASLC2A1PAX8
SCHEMBL4687414 0.90 DHFR (0.55) DHFRADORA2ASLC2A1F2R
Trifluoroacetic Acid SCHEMBL4692041 0.89 DHFR (0.41) DHFRSLC2A1PAX8
Trifluoroacetic Acid SCHEMBL4690346 0.89 DHFR (0.41) DHFRSLC2A1PAX8
Trifluoroacetic Acid SCHEMBL4688116 0.89 DHFR (0.41) DHFRSLC2A1PAX8F2RHSP90AA1
Trifluoroacetic Acid SCHEMBL4690832 0.89 DHFR (0.40) DHFRSLC2A1PAX8
Trifluoroacetic Acid SCHEMBL4692244 0.87 DHFR (0.42) DHFRADORA2ASLC2A1PAX8HSP90AA1
Trifluoroacetic Acid SCHEMBL4688889 0.87 DHFR (0.39) DHFRSLC2A1
Trifluoroacetic Acid SCHEMBL4687864 0.86 PAX8 (0.41) DHFRSLC2A1PAX8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7262297-B2 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors HOFFMANN-LA ROCHE INC. (US) 2007-08-28 US claimed
US-20040235872-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors BERTHEL STEVEN JOSEPH (US) 2004-11-25 US claimed
EP-1628979-B1 DIAMINOPYRROLOQUINAZOLINES COMPOUNDS AS PROTEIN TYROSINE PHOSPHATASE INHIBITORS HOFFMANN LA ROCHE (CH) 2008-03-19 EP disclosed
US-20070270445-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors BERTHEL STEVEN J 2007-11-22 US disclosed
US-7262297-B2 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors HOFFMANN-LA ROCHE INC. (US) 2007-08-28 US disclosed
US-20040235872-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors BERTHEL STEVEN JOSEPH (US) 2004-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040235872-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors PTPN5, PPP5C, PTP4A2 DHFR 289/4885ADORA2A 2090/4885PIK3CD 556/4885
US-20070270445-A1 Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors PTPN5, DUSP15, PPP5C DHFR 339/4885ADORA2A 1770/4885PIK3CD 652/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.